FN2 Earnings Intelligence

Novo Nordisk A/S earnings overview

Latest Novo Nordisk A/S (NVO) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportNovo Nordisk A/S reports Wednesday, Nov 4, 2026 · Before market openConsensus EPS $0.73 · consensus revenue $11.07B
NVO FY2026 Q3 · Calendar Q4 2026

Novo Nordisk A/S

Q3 analysis points to ongoing GLP-1 volume growth—especially Wegovy pill uptake—as a near-term growth support, while price erosion, loss of exclusivity and payer pressure temper confidence in durability.

EPS surprise—
Market move+6.4%

Get the NVO recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.